Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Youjiang Medical University for Nationalities | China

A cross-disciplinary researcher specializing in pharmaceutical and analytical chemistry, with expertise in integrating traditional herbal medicine and modern nanotechnology. Research focuses on isolating bioactive compounds, developing hydrogel-based medical materials, and designing nanoparticle and vaccine systems for cancer therapy. Has led multiple national and regional research projects, published extensively in peer-reviewed journals, and contributed to advancements in biomaterials and drug development. Work also includes metabolomics and mass spectrometry imaging. Actively involved in academic collaborations, editorial responsibilities, and professional organizations, supporting innovation in pharmaceutical sciences and translational medicine.

 

Citation Metrics (Scopus)

800
600
400
200
100
50
0

Citations
718

Documents
16

h-index
10

Citations

Documents

h-index

Featured Publications

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Maulana Abul Kalam Azad University of Technology | India

Rahul Das Gupta is a biotechnology researcher with expertise in cancer biology, nanomedicine, and computational drug discovery. His work focuses on exosome-based liquid biopsy for early brain cancer detection and in-silico screening of plant-derived anticancer compounds targeting oncogenic pathways. He has synthesized bio-metallic nanoparticles using medicinal plant extracts and evaluated their antimicrobial and cytotoxic potential through experimental and computational approaches, including EGFR and VEGFR interaction studies. Skilled in molecular biology, cell culture, bioinformatics, and advanced characterization techniques, he integrates laboratory research with computational analysis. His publication in Biochemical and Biophysical Research Communications highlights his contributions to translational cancer research.

Citation Metrics (Google Scholar)

2
1.5
1
0.5
0

Citations
2

h-index
1

i10-index
0

Citations

h-index

i10-index

Featured Publications

May Morris | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Dr. May Morris | Cancer Cell Biology | Women Researcher Award

IBMM / CNRS | France

Dr. May C. Morris is a CNRS Research Director (DR2) leading the “Biosensors and Inhibitors Group” within the Cellular Pharmacology Team at IBMM, University of Montpellier. Her research focuses on cell cycle biology, cancer, kinases and phosphatases, and peptide/protein biochemistry. She specializes in biophysical studies of protein interactions, fluorescent biosensor engineering, cell-penetrating peptide technologies, intracellular targeting, and high-throughput screening of small molecules. Dr. Morris has extensive experience in designing peptide and allosteric kinase inhibitors, as well as advanced cell culture and fluorescence imaging. Her career includes leadership roles at CNRS and postdoctoral research at the Scripps Research Institute.

Citation Metrics (Scopus)

8000
6000
4000
2000
200
100
0

Citations
7,564

Documents
94

h-index
36

Citations

Documents

h-index

Featured Publications

Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Hongjin Liu | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Hongjin Liu | Cancer Cell Biology | Research Excellence Award

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | China

Hongjin Liu is a medical oncologist whose research centers on cancer biology, therapeutic resistance, and tumorigenesis. His work spans molecular oncology, hepatocellular carcinoma, and mechanisms of somatic mutagenesis across human tissues. He has contributed to high-impact studies published in Nature and Signal Transduction and Targeted Therapy, including investigations uncovering the landscape of somatic mutations in normal tissues and the critical role of VAV2 in DNA repair and radiotherapy resistance. His research also explores noncoding RNA–mediated regulatory networks in liver cancer, notably identifying the oncogenic function of ELF3-AS1 through its modulation of the miR-98-5p/CPSF4 axis. Collectively, his publications provide important insights into genomic instability, tumor microenvironment dynamics, and potential molecular targets for improving therapeutic outcomes. His translational research aims to bridge molecular mechanisms with clinical oncology to support precision cancer treatment and advance strategies for overcoming therapy resistance.

Profile: Orcid

Featured Publications: 

1. Ge, P., Niu, S., Fang, M., Xu, Q., Zhang, W., Xu, J., Yang, F., Wang, Y., Shi, T., & Liu, H. (2025). ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis. Nucleosides, Nucleotides & Nucleic Acids.

2. Zhang, W., Liu, Z., Liu, H., Huang, Z., Huang, X., Xu, L., Che, X., & Zhan, Z. (2025). The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: A meta-analysis. Frontiers in Immunology.

3. Liu, W., Miao, C., Zhang, S., Liu, Y., Niu, X., Xi, Y., Guo, W., Chu, J., Lin, A., Liu, H., Yang, X., Chen, X., Zhong, C., Ma, Y., Wang, Y., Zhu, S., Liu, S., Tan, W., Lin, D., & Wu, C. (2021). VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduction and Targeted Therapy, 6(9), 2906–2919.

4. Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., Chen, Y., Miao, C., Liu, H., Wang, Y., Ma, Y., Xu, D., Lin, D., Huang, Y., Wang, J., Bai, F., & Wu, C. (2021). A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 597(7876), 398–403.

5. Chen, Y., Zeng, Q., Liu, X., Fu, J., Zeng, Z., Zhao, Z., Liu, Z., Bai, W., Dong, Z., & Liu, H. (2018). LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Management and Research, 10, 6345–6358.

Yanqi Dang | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Yanqi Dang | Cancer Cell Biology | Editorial Board Member

Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032 | China

The researcher focuses on the epigenetic regulation of metabolic diseases and tumorigenesis, with major contributions in colorectal cancer (CRC) diagnostics, mechanisms, and traditional Chinese medicine (TCM)-based interventions. In early CRC detection, the team performed transfer RNA (tRNA) sequencing and identified two key tRFs—tRF-Tyr-GTA-081 (downregulated) and tRF-Ala-AGC-060 (upregulated)—whose combined diagnostic model demonstrated strong performance for colorectal neoplastic lesions and cancer, outperforming traditional markers such as CEA and CA199. Multi-omics analyses of mRNAs, miRNAs and circRNAs identified three circRNAs with predictive value for adenoma–carcinoma transition. Through DNA hydroxymethylation sequencing, ZW10 emerged as a prognostic-related marker, and its circulating hydroxymethylation level showed high accuracy for early CRC detection. Mechanistic studies revealed that METTL3 regulates CRB3 in an m6A-dependent manner to modulate HIPPO signaling, while DNMT3B- and TET2-mediated epigenetic modifications jointly control PGC-1α to promote CRC progression. In therapeutic research, Scutellaria baicalensis Tang, Sijunzi Tang, and related monomers are under investigation for anti-CRC effects. In metabolic disease research, Ling-Gui-Zhu-Gan decoction and cinnamaldehyde were shown to improve steatosis and insulin resistance in NAFLD, supporting the TCM concept of “phlegm-beverage.” Current studies focus on lean NAFLD, demonstrating that METTL14 regulates TIM3 to influence disease development, and that GJLZ decoction alleviates steatosis and inflammation by enhancing this pathway.

Profile: Scopus

Featured Publications:

Ma, J., …, & al. (2025). Regulation of histone H3K27 methylation in inflammation and cancer.

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Yi Zhang | Tumor Immunology | Best Researcher Award

Published on by Cell Biologist

Prof. Yi Zhang | Tumor Immunology | Best Researcher Award

The First Affiliated Hospital of Zhengzhou University | China

Prof. Yi Zhang is a globally recognized leader in genetically engineered cell therapy and translational immuno-oncology research. Over the past 36 years, he has made pioneering contributions to overcoming major barriers in cell therapy and advancing its clinical applications worldwide. His extensive research has produced 290 SCI-indexed publications, including 11 ESI top 1% highly cited papers, accumulating more than 14,000 citations and an h-index of 66. Prof. Zhang’s groundbreaking innovations include identifying the novel CAR-T therapeutic target CD276 for solid tumors, developing gene-editing technologies to reduce PD-1–mediated immunosuppression, and creating novel cytokines and culture protocols that enhance immune cell stemness and anti-tumor function. He has also led the development of CAR-T cells that normalize tumor vasculature and improve infiltration, significantly enhancing therapeutic efficacy. With 46 invention patents (17 authorized) and over 80 million yuan in technology transfers, his work bridges basic science and clinical application through an integrated “industry-university-research” platform. As principal investigator, he has directed more than 52 clinical trials—29 targeting solid tumors, the highest number globally—resulting in improved outcomes and even clinical cures for advanced cancer patients. His leadership in establishing national standards and safety protocols has also shaped the regulation and global best practices in cell therapy.

Profile: Orcid

Featured Publications:

Gao, Y., Liu, S., Huang, Y., Wang, H., Zhao, Y., Cui, X., Peng, Y., Li, F., & Zhang, Y. (2024, December 3). CAR T cells engineered to secrete IFNκ induce tumor ferroptosis via an IFNAR/STAT1/ACSL4 axis. Cancer Immunology Research.

Huang, Y., Cao, R., Wang, S., Chen, X., Ping, Y., & Zhang, Y. (2025, December 31). In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Human Vaccines & Immunotherapeutics.

Li, J., Wang, D., Zhang, Z., Sun, K., Lei, Q., Zhao, X., Huang, J., Wang, L., & Zhang, Y. (2025, June 1). Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer. The Journal of Immunology.

Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2025, March 5). Correction: Immunosenescence: A key player in cancer development. Journal of Hematology & Oncology.

Ping, Y., Fan, Q., & Zhang, Y. (2025, February). Modulating lipid metabolism improves tumor immunotherapy. Journal for ImmunoTherapy of Cancer.

Hu, W., Li, F., Liang, Y., Liu, S., Wang, S., Shen, C., Zhao, Y., Wang, H., & Zhang, Y. (2025, January). Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. Journal for ImmunoTherapy of Cancer.

Evgeny Deforzh | Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.

Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Vaclav Ranc | Palacký University in Olomouc | Czech Republic

Dr. Václav Ranc is a distinguished analytical chemist and data analyst with over 15 years of experience in academia and applied research. Based in the Czech Republic, he leads a research group at Palacký University Olomouc, specializing in nanotechnology, plasmonic and electronic nanosensors, and advanced analytical techniques. He holds a Ph.D. in Analytical Chemistry and a Habilitation in Physical Chemistry. Dr. Ranc has published over 80 peer-reviewed scientific articles and holds several international patents. He has secured and managed significant EU funding, including Horizon Europe and MSCA projects, showcasing his excellence in both research and project leadership. His expertise spans Raman spectroscopy, mass spectrometry, and LC/GC methods, coupled with data analysis in Python, Matlab, and R. He is a regular presenter at international conferences and a recognized innovator in the fields of biosensing and nanomaterials.

Publication Profiles: 

Google Scholar
Orcid
Scopus

Education:

Dr. Václav Ranc earned his MSc. in Analytical Chemistry from Palacký University Olomouc (UPOL) in 2005, where he focused on the discrimination of enantiomers using mass spectrometry techniques such as LC-MS and CE-MS. He continued at UPOL to complete his Ph.D. in Analytical Chemistry, specializing in chiral analysis with HPLC-MS and GC-MS. His academic trajectory culminated in a Habilitation in Physical Chemistry, reflecting his advancements in Raman microscopy, SERS, and mass spectrometry. Dr. Ranc’s education is deeply rooted in analytical and physical chemistry, with a significant emphasis on developing and applying sophisticated separation and detection techniques for complex biological and clinical samples. His academic background is further enriched by international research experiences in Sweden and Switzerland, where he worked on electroanalytical techniques and nanoLC-MS applications for neurotransmitter analysis.

Experience:

Dr. Václav Ranc currently serves as the Head of a Research Group at Palacký University Olomouc, managing a 20-member team focused on cutting-edge nanomaterials and analytical chemistry. He has led the group’s scientific, financial, and personnel management, improving research output by 30%. Previously, he worked as a Research Assistant in Switzerland and at Palacký University, where he developed analytical techniques for clinical and neurological studies using mass spectrometry. His earlier roles include assisting in electrochemical method development at Lund University and clinical toxicology at Faculty Hospital Olomouc. His leadership extends to managing multimillion-CZK budgets and delivering impactful results in EU-funded research projects. Throughout his career, he has seamlessly combined academic excellence with innovation, leading to patented technologies and industrial prototypes, while mentoring young researchers and collaborating with international scientific networks.

Honors & Awards:

Dr. Václav Ranc has received several national and international honors for his scientific excellence. Notable among them is the Golden Medal at the International Invent Arena for the innovative KeyLock authentication system. He also earned the Bronze Prize from MERCK’s Young Analytical Chemists Competition and was a Finalist for the prestigious Shimadzu Prize for Young Analytical Chemists. His awards reflect consistent recognition for his groundbreaking work in analytical chemistry and applied nanotechnology. These accolades underscore his ability to translate complex research into practical applications, particularly in biosensing, authentication systems, and advanced materials. Dr. Ranc’s career is marked by impactful innovations that bridge academic research with industry needs, affirming his role as a thought leader in his field. His awarded projects and patents have contributed significantly to medical diagnostics, material sciences, and anti-counterfeiting technologies.

Research Focus:

Dr. Ranc’s research focuses on analytical chemistry, nanotechnology, and biosensing. He specializes in Raman spectroscopy (including SERS), LC/GC-MS, and the development of plasmonic and electronic nanosensors. His work bridges basic science and applied innovation, emphasizing the synthesis of nanoparticles, development of authenticity verification systems, and detection of biomarkers in clinical diagnostics. His contributions to surface-enhanced Raman spectroscopy have led to the development of patented methods and tools, including test strips and analytical systems. Dr. Ranc’s interdisciplinary approach combines analytical method development, data analysis using Python, R, and Matlab, and project management of EU-funded research. His current Horizon Europe projects focus on medical applications of nanotechnology, contributing to improved diagnostics, drug delivery systems, and authenticity verification. Through collaborations with European research institutions and industries, Dr. Ranc is pushing the boundaries of next-gen biomedical and analytical technologies.

Publication Top Notes:

  1. Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy

  2. Highly Cytotoxic Copper(II) Mixed-Ligand Quinolinonato Complexes: Pharmacokinetic Properties and Interactions with Drug Metabolizing Cytochromes P450

  3. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy

  4. Polymer-Based Graphene Derivatives and Microwave-Assisted Silver Nanoparticles Decoration as a Potential Antibacterial Agent

  5. New Limits for Stability of Supercapacitor Electrode Material Based on Graphene Derivative

  6. Label-free Determination of Prostate Specific Membrane Antigen in Human Whole Blood by Magnetically Assisted SERS

  7. Cyanographene and Graphene Acid: Emerging Derivatives Enabling High-Yield and Selective Functionalization of Graphene

  8. Detection of Prosthetic Joint Infection Based on Magnetically Assisted Surface Enhanced Raman Spectroscopy

  9. Functional Nanosheet Synthons by Covalent Modification of Transition-Metal Dichalcogenides

  10.  Nanoporous Nitrogen-Doped Graphene Oxide/Nickel Sulfide Composite Sheets for Hydrogen and Oxygen Evolution

Conclusion:

In conclusion, Dr. Václav Ranc is an exceptional candidate for the Best Researcher Award, demonstrating a rare synergy of academic excellence, applied innovation, and impactful leadership. His contributions to analytical chemistry and nanotechnology have advanced both scientific understanding and practical diagnostic solutions. His impressive publication record, international collaborations, patent portfolio, and success in leading multimillion-euro projects set him apart as a researcher of outstanding merit. With minor expansion into global research programs and commercialization efforts, Dr. Ranc is poised to further amplify his already significant impact. For his sustained contributions to science, his ability to lead and innovate, and his commitment to solving real-world problems through chemistry and nanotechnology, Dr. Václav Ranc is highly deserving of the Best Researcher Award.